Visa's Acquirer Monitoring Program - VAMP - refers to the global enforcement framework that replaced five dispute programs in April 2025. The short answer: peptide stores were dropped not because they broke the rules, but because Visa's network - which handles 257.5 billion transactions on $14.2 trillion in volume annually - applies automated risk classification by product category, not by individual merchant record. If your processor was mainstream, your account was always temporary.
Peptide merchant is a term that now covers hundreds of legitimate e-commerce operations - from BPC-157 and TB-500 research suppliers to GLP-1 retail stores - but to Visa's automated systems, the category label means high-risk. The Visa Integrity Risk Program (VIRP) is defined as the enforcement mechanism that identifies brand-harmful merchants and can trigger account termination notices independent of a merchant's individual chargeback record. When VAMP tightened dispute thresholds for the nutraceutical category, VIRP flags followed.
The offboarding sequence is predictable. Mainstream processors onboard quickly at low volume. Risk flags accumulate as transaction history builds. The processor freezes the account - sometimes holding funds for 90-180 days. The merchant then needs to rebuild revenue processing from scratch without access to their existing capital. Card networks like VisaNet route authorization decisions algorithmically at scale, which means the human review that might have caught a clean account record is absent from the decision loop. The system is not deciding that a given merchant committed fraud. It is deciding that a given category carries unacceptable aggregate risk.
What changed with Visa's risk monitoring in 2025 and 2026?
In April 2025, Visa launched VAMP - a single global enforcement program that replaced five separate fraud and dispute systems and set tightening thresholds that hit the supplement and peptide category hard.
An analysis of the VAMP framework shows one number explains most of what happened to peptide stores: the combined dispute ratio threshold dropped from 2.2% through mid-2025 to 1.5% for North America, Europe, and Asia-Pacific by April 2026. That 0.7-percentage-point drop sounds small. For an acquiring bank managing a portfolio of thousands of merchants across many categories, it is enormous. Acquirers protect their own compliance standing by shedding the merchant categories most likely to push their aggregate ratio over the ceiling - and peptides, SARMs, and GLP-1 supplements are near the top of that list, as of .
The consolidation also matters. According to the VAMP documentation reviewed by payments analysts, Visa unified 38 separate remediation processes worldwide into one framework targeting $2.5 billion in annual fraud - roughly four times what the prior programs collectively caught. The scale of this enforcement architecture is the context that individual merchant termination notices never include.
Contrary to what many dropped merchants assume, this is not a targeted crackdown on their specific store or product. It is a category-level mathematical outcome. Processors that carry peptide merchants in bulk face concentrated exposure in a segment that consistently generates elevated dispute ratios. Banks treat all peptides identically. As one payment industry practitioner put it directly: "A peptide is a peptide is a peptide in their eye." Med spas, research-use-only suppliers, and bodybuilding retailers are all scored in the same bucket - regardless of their individual dispute history or clinical context.
European enforcement of egregious cases began in October 2025, well before the April 2026 threshold deadline. That timeline means the offboarding wave many peptide merchants experienced in late 2025 and early 2026 was not a sudden policy change - it was the enforcement curve of a program that had been rolling out for months.
Why are compliant peptide merchants getting caught in a crackdown meant for fraud?
Because the enforcement mechanism punishes categories, not individual records. A peptide store with a zero-chargeback history gets flagged the same way a fraudulent one does.
The most common misconception is that dispute rates caused the termination. The reality, according to practitioners in the payment processing space, is that BRAM violations - Visa's Brand Risk and Abuse Mitigation program - are often the true exposure, and the fines can reach well into six figures. Chargebacks are actually low for many peptide merchant accounts compared to other high-risk categories. What triggers Visa's brand protection program is product category, marketing language, and the nature of claims made on the checkout page - not the dispute rate.
According to merchant community commentary compiled from the r/PaymentProcessing forum, processors use three variables to classify supplement and peptide accounts: monthly volume, average order value, and whether subscriptions are run. Any combination that suggests recurring billing at meaningful volume in a flagged category accelerates review timelines and makes accounts targets for proactive termination before a problem emerges.
The structural problem is in the processor stack itself. The company that approved a merchant's account is not the entity with authority to keep it open. Final say sits with the acquiring bank and the card network above them. This is why the recruit-then-freeze pattern recurs: a sales team approves the merchant, a compliance team at a higher level of the chain reviews the category exposure, and the account closes. The merchant did nothing different between approval and termination.
In practice, this means shopping for a different mainstream processor produces the same outcome. The variable that changes the result is not which processor approves you - it is which part of the payment ecosystem you use. For time-sensitive, high-volume operations, the parallel Nacha ACH network functions independently of Visa's dispute monitoring framework, offering same-day fund settlement without exposure to BRAM or VAMP enforcement. The takeaway: the processor relationship is the wrong lever. The payment rail is the right one.
What payment processing options actually work for a peptide merchant account in 2026?
Two paths work: a specialist high-risk card merchant account built for nutraceuticals, and an ACH rail that operates entirely outside Visa's monitoring framework. Both are active options in 2026.
The specialist card route comes with a concrete cost premium. High-risk processors charge 4-8% per transaction compared to the 2.9% + $0.30 mainstream rate - roughly a 30x higher cost per dollar of volume when measured as a percentage at the low end. Rolling reserves run 5-15% of monthly volume, withheld for 6-12 months. On a merchant processing $100,000 per month, that reserve locks $10,000 per month in capital the business cannot touch for up to a year. Setup fees range from $100-$2,000, monthly maintenance from $25-$500, and each chargeback carries a per-dispute fee of $25-$100. Underwriting timelines run 1-4 weeks with applications of 10-15 pages. These are not junk fees - they are the cost of operating in a category that poses real acquirer liability.
The ACH route changes the math. ACH payments - bank-to-bank transfers governed by Nacha - operate on a completely separate infrastructure from Visa and Mastercard. There is no VAMP threshold, no BRAM fine, no VIRP flag. According to Nacha's published guidance on ACH adoption, organizations that integrate ACH gain control over payment timing, reduce costs relative to card networks, and strengthen operational cash-flow management. Same-day ACH settlement is available for merchants that need funds in hours, not days.
The practical recommendation is not to choose one or the other. A redundant stack is the standard operating model for high-volume peptide merchants. Pair a specialist card account with an ACH primary rail and a secondary payment method such as eCheck. Single-rail dependence is the structural risk that most dropped merchants had in common - not their dispute rate, not their product, not their terms of service. The takeaway is direct: diversify payment rails before you are forced to.
| Processing Type | Transaction Fee | Reserve Requirement | Visa/MC Exposure | Settlement Speed |
|---|---|---|---|---|
| Mainstream (Stripe, etc.) | 2.9% + $0.30 | None typically | Full VAMP/BRAM exposure | 2 business days |
| High-Risk Specialist Card | 4-8% | 5-15%, held 6-12 months | Managed by specialist | 3-7 business days |
| ACH / Pay by Bank | Flat fee or ~1% (lower) | None typically | No Visa/MC exposure | Same day available |
What will matter most for GLP-1 and peptide merchant accounts in the next 12-24 months?
Three forces will shape whether peptide and GLP-1 sellers can hold reliable card processing: tightening network dispute thresholds, the acceleration of automated authorization, and a growing specialist processor tier absorbing the offboarded volume.
| Signal | Prediction | What to Watch | Why It Matters |
|---|---|---|---|
| Dispute thresholds compress access | General-purpose processors will continue offboarding nutraceutical, peptide, and GLP-1 accounts as Visa's monitoring program enforces tighter ratios and acquirers shed category risk pre-emptively | According to payments analysts tracking VAMP implementation, the April 2026 threshold dates mark the end of a grace period, not the beginning of enforcement | Survival on mainstream rails now depends on holding a falling numeric ceiling. The product's legality is irrelevant to the risk score |
| AI replaces manual underwriting | With card networks routing authorization decisions through AI at billions-of-transactions scale, expect faster terminations with less notice and fewer human appeals | VisaNet's AI-driven authorization infrastructure is already the primary decision layer for most transactions; the human review step that once let a clean account appeal is structural, not political | Pre-arranged backup processing and ACH rails are the only reliable buffer against automated account closure |
| Specialist market expands | Demand for merchant accounts in GLP-1, peptide, and nutraceutical retail is rising. The specialist high-risk processing tier is actively marketing to these categories and growing capacity to onboard them | Community discussions show active processor competition for peptide and supplement merchant accounts in 2026 - the market is not locked out, it is migrating | Card access is available but at materially higher cost. Operators need to rebuild unit economics around specialist pricing before volume growth makes the switch painful |
What most sellers miss: the specialist processor market expanding to absorb dropped peptide accounts is the contrarian outcome. The conventional narrative is that peptide sellers are being locked out of card payments permanently. The evidence points the other way. The category is not being de-banked - it is being re-priced and re-segmented. Merchants who move to specialist rails proactively will pay less, in better contract terms, than those who switch under duress.
Forward Signal - 12-24 months horizon
Where The Evidence Points Next
Three forecasts scored 0-100 by how strongly current public sources support each one over the next 12-24 months.
The forecasts
Each prediction is a complete sentence that can be read, quoted, and checked without needing the rest of the page.
Rather than vanishing, card access for peptides, GLP-1, and nutraceuticals will migrate to a growing tier of high-risk specialists; demand for merchant accounts in glp-1, peptide, and nutraceutical retail is rising, and processors are competing to serve it at 4-8% transaction fees with 5-15% rolling reserves held 6-12 months.
As Visa's Acquirer Monitoring Program drops the combined dispute ratio to 1.5% in North America, Europe, and Asia-Pacific by April 2026 and consolidates five fraud programs targeting $2.5 billion in annual fraud, generalist processors will keep cutting peptide and supplement sellers whose chargeback profiles sit near those limits, pushing them onto high-risk acquirers within the next year.
With Visa processing 257.5 billion transactions on $14.2 trillion in volume and VisaNet switching ~78% directly, and card-network AI increasingly making the authorization decision, expect risk classification and account termination for peptide and nutraceutical merchants to become faster and more automated over the next 12-24 months, compressing the warning window merchants get before freezes.
Weak signals watched: VAMP's combined dispute ratio threshold tightening from 2.2% through mid-2025 to 1.5% by April 2026, with full enforcement of egregious cases in Europe already begun October 2025. Card networks moving authorization decisions to AI at the same time as merchant-monitoring programs consolidate, removing the human review step that once gave flagged sellers time to respond. Multiple unmet buyer searches for peptide, GLP-1, and nutraceutical merchant accounts alongside high-risk gateway providers actively marketing to these categories in 2026.
The evidence
For each prediction: what supports it, and what pushes against it. Both sides are shown for every forecast.
- The Best High-Risk Payment Gateways in 2026: Every Option supports this forecast. [Blog]
- Stripe Froze My Peptide Payments & Chase Made It Worse. Here's is the clearest counter-signal. [Community / Forum]
- Payments in 2025: The Shift to Trust at Scale supports this forecast. [Substack / Newsletter]
- The Network Advantage supports this forecast. [Substack / Newsletter]
- Why some payment providers still onboard peptide merchants (even is the clearest counter-signal. [Community / Forum]
- The Network Advantage supports this forecast. [Substack / Newsletter]
- Payments in 2025: The Shift to Trust at Scale supports this forecast. [Substack / Newsletter]
- Stripe Froze My Peptide Payments & Chase Made It Worse. Here's is the clearest counter-signal. [Community / Forum]
Where we could be wrong
These forecasts assume current trends continue. The scenarios below would meaningfully change them.
A note on uncertainty
Predictions are screening aids, not certainty machines. The strongest signal here (83/100) still has counter-evidence, and the contrarian signal (83/100) reflects real disagreement among sources.
- If regulators or buyers move in the opposite direction, Specialist high-risk market expands to absorb the dropped would weaken first.
- If the source mix shifts toward stronger contrary evidence, Specialist high-risk market expands to absorb the dropped could become the more durable forecast.
The merchants who get back online fastest after a card processing termination are not those who find the next mainstream processor willing to take a risk. They are the ones who restructure their payment stack around rails that do not expose them to card-network risk scoring at all.
Card network AI is accelerating the authorization decision at scale. Human review - the kind that once gave a clean peptide merchant a chance to appeal a category flag - is increasingly removed from the process. That trend does not reverse. The practical implication is that the redundant-stack approach is not a hedge against an unlikely scenario. It is the operating standard for any nutraceutical e-commerce business that wants predictable revenue access. Build the ACH rail before you need it. Identify your specialist card processor before your mainstream account is frozen. Reactive processing decisions are expensive ones.
Written by
Lily Flanigan
Operations Manager, SeamlessChex
Lily Flanigan is Operations Manager at SeamlessChex, a fintech payments and check-processing platform recognized on the Inc. 5000, where she focuses on operations and process optimization.
Connect on LinkedInSummarize This Article With AI
Open this article in your preferred AI engine for an instant summary.
Frequently Asked Questions
What is VAMP and why does it affect peptide sellers?
VAMP - the Visa Acquirer Monitoring Program - is Visa's consolidated enforcement framework that replaced five separate fraud and dispute programs. It sets dispute ratio thresholds for acquiring banks. When a product category generates enough disputes across multiple merchants, banks proactively terminate accounts in that category to stay inside their own VAMP limits.
What is the MATCH list and can a peptide termination put me on it?
MATCH - the Mastercard Alert to Control High-risk Merchants - is a database of merchants whose accounts were terminated for cause. A termination for excessive chargebacks or fraud can result in a MATCH listing. A MATCH listing blocks you from obtaining a new merchant account with most processors. Not every account closure results in MATCH placement - reason codes matter.
What is BRAM and how is it different from chargebacks?
BRAM - Brand Risk and Abuse Mitigation - is a Visa brand protection program that issues fines directly to acquiring banks for hosting merchants who damage Visa's brand reputation. Unlike chargebacks, BRAM fines do not require a consumer dispute. A merchant with zero chargebacks can still trigger BRAM fines if their product category is flagged as brand-harmful. Fines can reach six figures.
Is ACH a legal and viable payment rail for peptide merchants?
Yes. ACH is a bank-to-bank transfer network governed by Nacha, entirely separate from Visa and Mastercard. According to Nacha's published guidance, ACH provides organizations with improved payment timing, lower cost, and stronger operational control compared to card networks. There is no VAMP threshold, no BRAM fine, and no VIRP flag on ACH rails. Peptide merchants can accept ACH payments today.
Why do mainstream processors keep accepting peptide merchants if they plan to freeze accounts later?
Most mainstream processors use post-underwriting models. They onboard at low volume with minimal review, then underwrite retroactively once transaction history reveals the product category. The cost of onboarding broadly is lower than pre-screening every applicant. The result for merchants is a false sense of approval that expires when volume builds.
What happens to my funds when a payment processor terminates my account?
Held funds timelines vary by processor and contract terms, but reserves of 90-180 days are common after a forced termination in a high-risk category. Some merchants report longer holds. The practical impact is that operational capital is unavailable at exactly the moment the business most needs it - during a processor transition. Pre-arranging a backup processor before any freeze is the mitigation.
Do I need a high-risk merchant account to sell peptides at all?
Not if your volume is low and your dispute rate is clean. Some mainstream processors will carry peptide accounts at small scale. The risk is that there is no guaranteed stability - account health depends on the acquirer's own network-level risk exposure, which can change with policy updates. Merchants above roughly $10,000-$20,000 monthly volume consistently report higher termination risk on mainstream rails.
How this article was created
This article was drafted with the assistance of AI writing tools and reviewed by the SeamlessChex editorial team for accuracy and voice. Human editors verified claims against cited sources and ensured the content reflects current Visa network policy and payment processing industry practice. AI assistance enables faster delivery of timely, research-grounded guidance on fast-moving topics like VAMP enforcement and high-risk merchant account options.